|Bid||120.76 x 1800|
|Ask||137.05 x 1000|
|Day's Range||131.97 - 134.25|
|52 Week Range||103.00 - 149.07|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||28.55|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
During the Lightning Round of Mad Money Thursday night, Jim Cramer mentioned to one caller that he also likes Charles River Laboratories International Inc. In the daily bar chart of CRL, below, we can see some bearish signals. The On-Balance-Volume (OBV) line shows weakness from late April telling us that sellers of CRL have become more aggressive.
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CRL totaled $7 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Charles River earnings of $1.40 a share, on an adjusted basis, on $604.6 million in sales beat first-quarter estimates Tuesday. But shares closed down on worries of a China trade war.
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Massachusetts-based company said it had profit of $1.11 per share. Earnings, adjusted for non-recurring costs, came to $1.40 per share. The results surpassed Wall Street expectations. The ...
An unidentified group of hackers recently broke into Charles River Laboratories’ information system and copied some drug developers’ data, the company disclosed Tuesday.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E ratio and reflect on what it tells us about the...
Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price increase onRead More...